What is Wedbush’s Estimate for Scholar Rock FY2028 Earnings?

Scholar Rock Holding Co. (NASDAQ:SRRK) – Investment analysts at Wedbush boosted their FY2028 EPS estimates for Scholar Rock in a report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will earn $0.39 per share for the year, up from their previous estimate of $0.33. Wedbush currently has a “Outperform” rating and a $37.00 target price on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.37) per share.

SRRK has been the topic of a number of other reports. HC Wainwright raised their price objective on Scholar Rock from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. Piper Sandler raised their target price on Scholar Rock from $28.00 to $42.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. BMO Capital Markets lifted their price objective on Scholar Rock from $34.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, October 11th. Finally, JPMorgan Chase & Co. lifted their price objective on Scholar Rock from $18.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, October 14th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $34.00.

Scholar Rock Trading Up 0.4 %

NASDAQ SRRK opened at $27.50 on Thursday. The stock’s 50-day simple moving average is $20.24 and its two-hundred day simple moving average is $13.53. Scholar Rock has a twelve month low of $6.76 and a twelve month high of $35.38. The company has a quick ratio of 6.04, a current ratio of 6.04 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $2.20 billion, a price-to-earnings ratio of -11.70 and a beta of 0.47.

Institutional Trading of Scholar Rock

Several institutional investors have recently modified their holdings of SRRK. Clearbridge Investments LLC acquired a new stake in shares of Scholar Rock in the second quarter valued at about $6,223,000. Candriam S.C.A. acquired a new position in shares of Scholar Rock in the second quarter valued at approximately $6,201,000. Fisher Asset Management LLC grew its holdings in shares of Scholar Rock by 593.6% in the third quarter. Fisher Asset Management LLC now owns 734,019 shares of the company’s stock valued at $5,879,000 after purchasing an additional 628,186 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Scholar Rock by 159.2% in the second quarter. Millennium Management LLC now owns 925,584 shares of the company’s stock valued at $7,710,000 after purchasing an additional 568,512 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in Scholar Rock by 1,051.3% during the 2nd quarter. Marshall Wace LLP now owns 487,285 shares of the company’s stock worth $4,059,000 after acquiring an additional 444,961 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Insider Buying and Selling

In other Scholar Rock news, insider Tracey Sacco sold 30,000 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $25.62, for a total value of $768,600.00. Following the completion of the transaction, the insider now owns 49,285 shares of the company’s stock, valued at approximately $1,262,681.70. This trade represents a 37.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Srinivas Akkaraju sold 1,175,713 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $29.25, for a total transaction of $34,389,605.25. Following the transaction, the director now directly owns 5,612,896 shares of the company’s stock, valued at approximately $164,177,208. This trade represents a 17.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,413,889 shares of company stock valued at $40,652,551 in the last ninety days. 19.20% of the stock is owned by company insiders.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.